Why I’m Bullish on European Market Access (Part 1 of 4)

There has been much discussion in market access circles over the last couple of years about the Inflation Reduction Act and its impact on US market access. Less attention has been paid to the <a href="https://health.ec.europa.eu/health-technology-assessment/regulation-health-technology-assessment_en" rel="noopener ugc nofollow" target="_blank">JCA — Joint Clinical Assessment</a> — coming to Europe. Next week, as many of us in the access community gather at the <a href="https://www.terrapinn.com/conference/pharma-pricing/index.stm" rel="noopener ugc nofollow" target="_blank">EPA conference</a> in Amsterdam, the JCA is top of mind. Like any regulatory change, the impact of JCA is what we make of it. And I want to share in the next few days why I see JCA and other changes in European Market Access as an opportunity for innovative leaders in pharma and payers to change the way they work in ways that can increase access for patients to the new therapies they need. <a href="https://medium.com/@nathansigworth/why-im-bullish-on-european-market-access-part-1-of-4-e0d0ea2ebf96">Click Here</a>